The safety of COVID-19 vaccination in rheumatic patients treated with biological (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) remains poorly explored.
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs
De Stefano, Ludovico;Balduzzi, Silvia;Bogliolo, Laura;D'Onofrio, Bernardo;di Lernia, Michele;Mauric, Eleonora;Milanesi, Alessandra;Brandolino, Fabio;Rocca, Clarissa;Chiricolo, Sofia;Manzo, Antonio;Montecucco, Carlomaurizio;Bugatti, Serena
2022-01-01
Abstract
The safety of COVID-19 vaccination in rheumatic patients treated with biological (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) remains poorly explored.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
